Evidence map›Paper›PMID 25918841›Full record

SynthesisPloS one2014

A genome wide association study links glutamate receptor pathway to sporadic Creutzfeldt-Jakob disease risk.

Pascual Sanchez-Juan, Matthew T Bishop, Gabor G Kovacs, Miguel Calero, Yurii S Aulchenko, Anna Ladogana, Alison Boyd, Victoria Lewis, Claudia Ponto, Olga Calero and 19 more

Open access · goldAbstract readMeta-AnalysisMulticenter Study
In one paragraph

Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Genetic susceptibility to infectious diseases: Current status and future perspectives from genome-wide approaches.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2018
    Review
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 13 institutions in 9 countries.

Pascual Sanchez-JuanNeurology Department, University Hospital "Marqués de Valdecilla". Instituto de Investigación "Marqués de Valdecilla" IDIVAL and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED). Santander, Spain.
Matthew T BishopThe National Creutzfeldt-Jakob disease Research and Surveillance Unit, University of Edinburgh, United Kingdom.
Gabor G KovacsInstitute of Neurology, Medical University Vienna, Vienna, Austria.
Miguel CaleroChronic Disease Programme and CIBERNED. Carlos III Institute of Health. Madrid. Spain; Alzheimer Disease Research Unit, CIEN Foundation, Carlos III Institute of Health, Alzheimer Center Reina Sofia Foundation, Madrid, Spain.
Yurii S AulchenkoDepartment of Epidemiology, Erasmus Medical Centre, Rotterdam, the Netherlands; Institute of Cytology and Genetics SB RAS, Novosibirsk, Russia; Novosibirsk State University, Novosibirsk, Russia.
Anna LadoganaDepartment of Cell Biology and Neurosciences Instituto Superiore di Sanità, Roma, Italy.
Alison BoydDepartment of Pathology, The University of Melbourne, Parkville, 3010, Australia.
Victoria LewisDepartment of Pathology, The University of Melbourne, Parkville, 3010, Australia.
Claudia PontoDepartment of Neurology, Clinical Dementia Centre, University Medical Center and German Center for Neurodegenerative Diseases (DZNE)-site Göttingen, Göttingen, Germany.
Olga CaleroChronic Disease Programme and CIBERNED. Carlos III Institute of Health. Madrid. Spain.
Anna PoleggiDepartment of Cell Biology and Neurosciences Instituto Superiore di Sanità, Roma, Italy.
Ángel CarracedoFundación Pública Galega de Medicina Xenómica, CIBERER, Grupo de Medicina Xenómica-Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Center of Excellence in Genomic Medicine Research (CEGMR), King Abdulaziz University, Jeddah, KSA.
Sven J van der LeeDepartment of Epidemiology, Erasmus Medical Centre, Rotterdam, the Netherlands.
Thomas StröbelInstitute of Neurology, Medical University Vienna, Vienna, Austria.
Fernando RivadeneiraDepartment of Epidemiology, Erasmus Medical Centre, Rotterdam, the Netherlands; Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.
Albert HofmanDepartment of Epidemiology, Erasmus Medical Centre, Rotterdam, the Netherlands.
Stéphane HaïkSorbonne Universités, UPMC Univ Paris 06 UMR S 1127, and Inserm, U 1127, and CNRS UMR 7225, and ICM, F-75013, Paris, France; AP-HP, Hôpital de la Pitié Salpêtrière, Cellule Nationale de Référence des maladies de Creutzfeldt-Jakob, F-75013, Paris, France.
Onofre CombarrosNeurology Department, University Hospital "Marqués de Valdecilla". Instituto de Investigación "Marqués de Valdecilla" IDIVAL and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED). Santander, Spain.
José BercianoNeurology Department, University Hospital "Marqués de Valdecilla". Instituto de Investigación "Marqués de Valdecilla" IDIVAL and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED). Santander, Spain.
Andre G UitterlindenDepartment of Epidemiology, Erasmus Medical Centre, Rotterdam, the Netherlands; Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.
Steven J CollinsDepartment of Pathology, The University of Melbourne, Parkville, 3010, Australia.
Herbert BudkaInstitute of Neurology, Medical University Vienna, Vienna, Austria.
Jean-Philippe BrandelSorbonne Universités, UPMC Univ Paris 06 UMR S 1127, and Inserm, U 1127, and CNRS UMR 7225, and ICM, F-75013, Paris, France; AP-HP, Hôpital de la Pitié Salpêtrière, Cellule Nationale de Référence des maladies de Creutzfeldt-Jakob, F-75013, Paris, France.
Jean Louis LaplancheService de biochimie et biologie moleculaire, Laboratoire associé au CNR "ATNC", Hôpital Lariboisiére, AP-HP, Paris, France.
Maurizio PocchiariDepartment of Cell Biology and Neurosciences Instituto Superiore di Sanità, Roma, Italy.
Inga ZerrDepartment of Neurology, Clinical Dementia Centre, University Medical Center and German Center for Neurodegenerative Diseases (DZNE)-site Göttingen, Göttingen, Germany.
Richard S G KnightThe National Creutzfeldt-Jakob disease Research and Surveillance Unit, University of Edinburgh, United Kingdom.
Robert G WillThe National Creutzfeldt-Jakob disease Research and Surveillance Unit, University of Edinburgh, United Kingdom.
Cornelia M van DuijnDepartment of Epidemiology, Erasmus Medical Centre, Rotterdam, the Netherlands.
Erasmus University Rotterdam · NLIstituto Superiore di Sanità · ITThe University of Melbourne · AUUniversity of Edinburgh · GBAssistance Publique – Hôpitaux de Paris · FRGerman Center for Neurodegenerative Diseases · DEInstituto de Investigación Marqués de Valdecilla · ESBiomedical Research Networking Center on Neurodegenerative Diseases · ESCentro de Investigación Biomédica en Red · ESErasmus MC · NLFundacion Centro De Investigacion De Enfermedades Neurologicas · ESInserm · FRUniversidade de Santiago de Compostela · ES

Funding

Wellcome Trust
6 · The paper itself

Abstract

We performed a genome-wide association (GWA) study in 434 sporadic Creutzfeldt-Jakob disease (sCJD) patients and 1939 controls from the United Kingdom, Germany and The Netherlands. The findings were replicated in an independent sample of 1109 sCJD and 2264 controls provided by a multinational consortium. From the initial GWA analysis we selected 23 SNPs for further genotyping in 1109 sCJD cases from seven different countries. Five SNPs were significantly associated with sCJD after correction for multiple testing. Subsequently these five SNPs were genotyped in 2264 controls. The pooled analysis, including 1543 sCJD cases and 4203 controls, yielded two genome wide significant results: rs6107516 (p-value=7.62x10-9) a variant tagging the prion protein gene (PRNP); and rs6951643 (p-value=1.66x10-8) tagging the Glutamate Receptor Metabotropic 8 gene (GRM8). Next we analysed the data stratifying by country of origin combining samples from the pooled analysis with genotypes from the 1000 Genomes Project and imputed genotypes from the Rotterdam Study (Total n=12967). The meta-analysis of the results showed that rs6107516 (p-value=3.00x10-8) and rs6951643 (p-value=3.91x10-5) remained as the two most significantly associated SNPs. Rs6951643 is located in an intronic region of GRM8, a gene that was additionally tagged by a cluster of 12 SNPs within our top100 ranked results. GRM8 encodes for mGluR8, a protein which belongs to the metabotropic glutamate receptor family, recently shown to be involved in the transduction of cellular signals triggered by the prion protein. Pathway enrichment analyses performed with both Ingenuity Pathway Analysis and ALIGATOR postulates glutamate receptor signalling as one of the main pathways associated with sCJD. In summary, we have detected GRM8 as a novel, non-PRNP, genome-wide significant marker associated with heightened disease risk, providing additional evidence supporting a role of glutamate receptors in sCJD pathogenesis.

Indexed as

Polymorphism, Single NucleotideCase-Control StudiesCreutzfeldt-Jakob SyndromeGenome-Wide Association StudyGermanyHumansNetherlandsPrion ProteinsPrionsReceptors, Metabotropic GlutamateSignal TransductionUnited Kingdommetabotropic glutamate receptor 8Prion ProteinsPrionsPRNP protein, humanReceptors, Metabotropic Glutamate

Identifiers

PMID25918841
PMCPMC4412535
OpenAlexW2157501255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.